Secretory defects in pediatric osteosarcoma result from downregulation of selective COPII coatomer proteins

Area of Science:

• Oncology
• Cell Biology
• Genomics

Background:

• Pediatric osteosarcomas (OS) are characterized by significant genomic instability, hindering targeted therapy development.
• A hallmark of OS is an unusually dilated endoplasmic reticulum (ER), suggesting a specific cellular defect.

Purpose of the Study:

• To investigate the molecular mechanism behind ER dilation in pediatric osteosarcomas.
• To explore the potential of targeting COPII vesicle components for therapeutic intervention.

Main Methods:

• Analysis of 108 patient tumor samples and patient-derived xenografts (PDXs).
• CRISPR activation technology to restore expression of COPII components SAR1A and SEC24D.
• Assessment of ER morphology, protein secretion, and tumor growth in xenograft models.

Main Results:

• The majority of OS samples exhibited reduced expression of four COPII vesicle components, leading to procollagen-I accumulation in the ER.
• Restoring SAR1A and SEC24D expression normalized ER morphology and improved secretion of collagen-I and other extracellular matrix (ECM) proteins.
• However, restoring only SAR1A and SEC24D did not inhibit orthotopic xenograft tumor growth.

Conclusions:

• Reduced COPII component expression is a conserved molecular signature driving ER dilation in pediatric osteosarcomas.
• While ER morphology can be corrected, targeting these specific COPII components alone may not be sufficient to halt OS tumorigenesis.
• Further research is needed to understand the broader implications of this ER phenotype in OS development.